Ikaros Deletions among Bulgarian Patients with Acute Lymphoblastic Leukemia/Lymphoma

The <i>Ikaros</i> zinc finger factor 1 is a transcription factor with a well-known role in B- and T-cell development. The deletions of <i>IKZF1</i> have an established significance in acute lymphoblastic leukemia, while reports on its prevalence and prognostic significance among ALL subtypes and regions vary. Breakpoint-specific qPCR is a practical method for testing of the most frequent types of <i>IKZF1</i> deletions, considering there is clustering of the deletion events. The most commonly reported deletions are Δ4-7, Δ4-8, Δ2-7, and Δ2-8, with deletion Δ4-7 being the most common one. We retrospectively administered a breakpoint-specific qPCR design for screening for the most frequent types of <i>IKZF1</i> deletions to 78 ALL patients that were diagnosed and treated between 2010 and 2022. We observed the products through gel electrophoresis, and we conducted descriptive statistics, EFS, and OS analyses. Our study found 19 patients with <i>IKZF1</i> deletions, with two subjects manifesting more than one deletion. The prevalence in the different subgroups was as follows: Ph/+/ B-ALL 46%, Ph/-/ B-ALL 30%, T-ALL/LBL 4%. There was a statistically significant difference in EFS of 39 vs. 0% in favor of patients without deletions (<i>p</i> = 0.000), which translated to a difference in OS of 49 vs. 0% (<i>p</i> = 0.001). This difference was preserved in the subgroup of Ph/-/ B-ALL, while there was no significant difference in the Ph/+/ B-ALL. The most frequently observed type of deletion (15 out of 19) was the Δ4-7. There is a strong negative prognostic impact of the <i>IKZF1</i> deletions at diagnosis in the observed population. <i>IKZF1</i> deletion testing through breakpoint-specific qPCR is a practical approach in diagnostic testing for this risk factor. <i>IKZF1</i> deletions may warrant treatment decisions and intensified treatment strategies to overcome the negative prognostic impact.